Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells

International Journal of Cancer

Volumn 133, Issue 5, 2013, Pages 1143-1152

  Damania, Dhwanil ^a   Roy, Hemant K ^b   Kunte, Dhananja ^b   Hurteau, Jean A ^b   Subramanian, Hariharan ^a   Cherkezyan, Lusik ^a   Krosnjar, Nela ^b   Shah, Maitri ^b   Backman, Vadim ^a  

^a Northwestern University   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

endocervix; endometrium; field carcinogenesis; nano architecture; ovarian cancer

Indexed keywords

COMPLEMENTARY DNA; MICRORNA; MICRORNA 187; MICRORNA 199; MICRORNA 211; MICRORNA 424; MICRORNA 432; MICRORNA 495; MICRORNA 674; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DNA METHYLATION; DRINKING BEHAVIOR; EARLY DIAGNOSIS; ENDOCERVICAL EPITHELIAL CELL; ENDOMETRIAL EPITHELIAL CELL; EPITHELIUM CELL; FEMALE; FIMBRIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYSTERECTOMY; MICROSCOPY; NANOCYTOLOGY; NANOIMAGING; OVARIAN CARCINOGENESIS; OVARY CANCER; PARTIAL WAVE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; RNA ISOLATION; SMOKING; UTERINE CERVIX MUCOSA;

ENDOCERVIX; ENDOMETRIUM; FIELD-CARCINOGENESIS; NANO-ARCHITECTURE; OVARIAN CANCER;

AGED; CELL TRANSFORMATION, NEOPLASTIC; CERVIX UTERI; ENDOMETRIUM; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NANOTECHNOLOGY; OVARIAN NEOPLASMS;

EID: 84879224284     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28122     Document Type: Article

References (50)

1. Kopelovich L, Henson DE, Gazdar AF, et al. Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect. Clin Cancer Res 1999; 5: 3899-905.
2. Backman V, Roy HK,. Light-scattering technologies for field carcinogenesis detection: a modality for endoscopic prescreening. Gastroenterology 2011; 140: 35-41.
3. Dakubo GD, Jakupciak JP, Birch-Machin MA, et al. Clinical implications and utility of field cancerization. Cancer Cell Int 2007; 7: 2.
4. Bernstein C, Bernstein H, Garewal H, et al. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res 1999; 59: 2353-7.
5. Anti M, Marra G, Armelao F, et al. Rectal epithelial cell proliferation patterns as predictors of adenomatous colorectal polyp recurrence. Gut 1993; 34: 525-30.
6. Hao CY, Moore DH, Chiu YS, et al. Altered gene expression in normal colonic mucosa of individuals with polyps of the colon. Dis Colon Rectum 2005; 48: 2329-35.
7. Polley AC, Mulholland F, Pin C, et al. Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucosa of patients with colorectal neoplasia. Cancer Res 2006; 66: 6553-62.
8. Alberts DS, Einspahr JG, Krouse RS, et al. Karyometry of the colonic mucosa. Cancer Epidemiol Biomarkers Prev 2007; 16: 2704-16.
9. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277-84.
10. Sidransky D,. The oral cavity as a molecular mirror of lung carcinogenesis. Cancer Prev Res 2008; 1: 12-4.
11. Bernstein C, Bernstein H, Payne CM, et al. Field defects in progression to gastrointestinal tract cancers. Cancer Lett 2008; 260: 1-10.
12. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
13. Clarke-Pearson DL,. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361: 170-7.
14. Karst AM, Drapkin R,. The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Med Rep 2011; 3: 22.
15. Levanon K, Crum C, Drapkin R,. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26: 5284-93.
16. Caldarella A, Crocetti E, Taddei GL, et al. Coexisting endometrial and ovarian carcinomas: a retrospective clinicopathological study. Pathol Res Pract 2008; 204: 643-8.
17. Widschwendter M, Apostolidou S, Jones AA, et al. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer 2009; 125: 2214-8.
18. Herrinton LJ, Voigt LF, Weiss NS, et al. Risk factors for synchronous primary endometrial and ovarian cancers. Ann Epidemiol 2001; 11: 529-33.
19. Russell P, Bannatyne PM, Solomon HJ, et al. Multifocal tumorigenesis in the upper female genital tract-implications for staging and management. Int J Gynecol Pathol 1985; 4: 192-210.
20. Subramanian H, Roy HK, Pradhan P, et al. Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res 2009; 69: 5357-63.
21. Subramanian H, Pradhan P, Liu Y, et al. Partial-wave microscopic spectroscopy detects subwavelength refractive index fluctuations: an application to cancer diagnosis. Opt Lett 2009; 34: 518-20.
22. Roy HK, Subramanian H, Damania D, et al. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res 2010; 70: 7748-54.
23. Damania D, Roy HK, Subramanian H, et al. Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization. Cancer Res 2012; 72: 2720-7.
24. Konda VJ, Cherkezyan L, Subramanian L,et al. Nanoscale differences assessed by partial wave spectroscopy in the field of esophageal cancer and Barrett's esophagus. Gastroenterology 2011; 140: S752-S752.
25. Subramanian H, Pradhan P, Liu Y, et al. Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells. Proc Natl Acad Sci USA 2008; 105: 20118-23.
26. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14: 2690-5.
27. Dahiya N, Morin PJ,. MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 2010; 17: F77-89.
28. Bartels CL, Tsongalis GJ,. MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009; 55: 623-31.
29. Damania D, Subramanian H, Tiwari AK, et al. Role of cytoskeleton in controlling the disorder strength of cellular nanoscale architecture. Biophys J 2010; 99: 989-96.
30. Pradhan P, Kumar N,. Localization of light in coherently amplifying random-media. Phys Rev B 1994; 50: 9644-7.
31. Davies HG, Wilkins MH,. Interference microscopy and mass determination. Nature 1952; 169: 541.
32. Kim JS, Pradhan P, Backman V, et al. The influence of chromosome density variations on the increase in nuclear disorder strength in carcinogenesis. Phys Biol 2011; 8: 015004.
33. Stypula Y, Crawford S, Subramanian H, et al. Understanding biological mechanisms of nuclear disorder strength in early carcinogenesis. Gastroenterology 2011; 140: S765-S6.
34. Cherkezyan L, Subramanian H, Stoyneva V, et al. Targeted alteration of real and imaginary refractive index of biological cells by histological staining. Opt Lett 2012; 37: 1601-3.
35. Ramus SJ, Elmasry K, Luo Z, et al. Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. Clin Cancer Res 2008; 14: 5840-8.
36. Gunderson CC, Fader AN, Carson KA, et al. Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477-82.
37. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-707.
38. Zhang Z, Bast RC, Yu YH, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90.
39. Booth M, Beral V, Smith P,. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60: 592-8.
40. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol 2008; 110: 408-17.
41. Tuma RS,. Origin of ovarian cancer may have implications for screening. J Natl Cancer Inst 2010; 102: 11-3.
42. Yang HJ, Liu VW, Tsang PC, et al. Comparison of human papillomavirus DNA levels in gynecological cancers: implication for cancer development. Tumour Biol 2003; 24: 310-6.
43. Boice JD, Jr, Engholm G, Kleinerman RA, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988; 116: 3-55.
44. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer I 2007; 99: 1634-43.
45. Hisada M, van den Berg BJ, Strickler HD, et al. Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control 2001; 12: 335-41.
46. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5: 167ra4.
47. Backman V, Kim JS, Pradhan P, et al. The influence of chromosome density variations on the increase in nuclear disorder strength in carcinogenesis. Phys Biol 2011; 8: 015004.
48. Pradhan P, Damania D, Joshi HM, et al. Quantification of nanoscale density fluctuations by electron microscopy: probing cellular alterations in early carcinogenesis. Phys Biol 2011; 8: 026012.
49. Boren T, Xiong Y, Hakam A, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009; 113: 249-55.
50. Urban N, Thorpe JD, Bergan LA, et al. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 2011; 103: 1630-4.